COVID-19 vaccine: Zydus Cadila to begin phase-2 clinical trials

Published: 05 August, 2020 12:35 IST | IANS | New Delhi

The company stated that the doses of the vaccine administered to healthy volunteers in phase I clinical trial, which began on July 15, were well tolerated

This image has been used for representational purposes
This image has been used for representational purposes

Drug firm Zydus Cadila on Wednesday announced that its plasmid DNA vaccine to prevent COVID-19 -- ZyCoV-D -- was found to be safe and well-tolerated in phase I clinical trial. The company will now commence phase II clinical trials from August 6.

The company stated that the doses of the vaccine administered to healthy volunteers in phase I clinical trial, which began on July 15, were well tolerated.

"We now begin the phase II clinical trials and look forward to evaluating the safety and immunogenicity of the vaccine in a larger population," said Pankaj R. Patel, Chairman of Zydus Cadila.

He also said that all the subjects in phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post-dosing for safety and for seven days thereafter and the vaccine was found to be very safe.

The statement came a day after Director General of Indian Council of Medical Research Balram Bhargava said that the DNA vaccine by Zydus Cadila has completed phase I trials and embarked on phase II at 11 sites.

Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit a high level of neutralisation of antibodies in animal studies.

The phase II trial will be evaluating the humoral and cellular immune response for the vaccine candidate in line with the current global clinical trial protocols in general.

With ZyCoV-D, the company has successfully established the DNA vaccine platform in the country using non-replicating and non-integrating plasmid carrying the gene of interest making it very safe.

The plasmid DNA when introduced into the host cells would be translated into the viral protein and will elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

Besides this, ICMR chief Balram Bhargava had also said that the inactivated virus vaccine by Bharat Biotech has completed its phase I study at 11 sites and has started its phase II study.

"There is no specific drug or vaccine available yet. The need for the vaccine is great and urgent but there is a dilemma - the pandemic is progressing rapidly and developing the vaccine may take time," he had said.

According to the ICMR, there are 141 vaccine candidates which are being studied the world over, out of which 26 are in different phases of the clinical trial. Three vaccines are in different phases of clinical testing in India.

Keep scrolling to read more news

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Sign up for all the latest news, top galleries and trending videos from Mid-day.com

Subscribe
loading image
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK